Glucose-Dependent Insulinotropic Polypeptide May Enhance Fatty Acid Re-esterification in Subcutaneous Abdominal Adipose Tissue in Lean Humans
Open accessThe DOI matches its Crossref record; 18 of the 19 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Glucose-dependent insulinotropic polypeptide (GIP) has been implicated in lipid metabolism in animals. In humans, however, there is no clear evidence of GIP effecting lipid metabolism. The present experiments were performed in order to elucidate the effects of GIP on regional adipose tissue metabolism. RESEARCH DESIGN AND METHODS: Eight healthy subjects were studied on four different occasions. Abdominal subcutaneous adipose tissue metabolism was assessed by measuring arterio-venous concentration differences and regional adipose tissue blood flow during GIP (1.5 pmol/kg/min) or saline infused intravenously alone or in combination with a hyperinsulinemic-hyperglycemic (HI-HG) clamp. RESULTS: During GIP and HI-HG clamp, abdominal subcutaneous adipose tissue blood flow, hydrolysis of circulating triacylglycerol (TAG) (P = 0.009), and glucose uptake (P = 0.03) increased significantly while free fatty acid (FFA) output (P = 0.04) and FFA/glycerol release ratio (P = 0.02) decreased compared with saline and HI-HG clamp. CONCLUSIONS: In conclusion, GIP in combination with hyperinsulinemia and slight hyperglycemia increased adipose tissue blood flow, glucose uptake, and FFA re-esterification, thus resulting in increased TAG deposition in abdominal subcutaneous adipose tissue.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GIP targets the white adipose tissue (Figure 1) improving its buffering capacity by promoting postprandial triglyceride storage and fatty acids re-esterification [196].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [196]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“TAG accumulation occurs during hyperinsulinaemic hyperglycemic clamps as a result of these metabolic processes [114].”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [114]
Experimental — accuracy not yet measuredIn the citing paper
“Additional research verified that GIP did not alter energy metabolism or appetite, nor did it alter TAG clearance in the absence of insulin when compared with saline infusion of lipid emulsions [114].”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [114]
In the citing paper
“In healthy lean humans, when infused alone, GIP did not modify the local metabolism in AT but it has been able to enhance the hydrolysis of TAG induced by insulin, glucose uptake and blood flow, at the same time reducing FFA output.”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [114]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inhibition of gastric inhibitory polypeptide signaling prevents obesity
Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., et al. (2002) · Nature Medicine · doi:10.1038/nm727 · Cited by 963
Self-citationIntegrative physiology of human adipose tissue
Frayn, K. N., Karpe, F., Fielding, B. A., Macdonald, I. A., & Coppack, S. W. (2003) · International Journal of Obesity · doi:10.1038/sj.ijo.0802326 · Cited by 467 · cited 2×
“Based on these findings, we hypothesized that GIP per se plays a role in the regulation of adipose tissue re-esterification of FFA, a process that is of central importance in adipose tissue handling of fatty acids (7,8).”
BackgroundDeacon, C. F., Nauck, M. A., Meier, J., Hücking, K., & Holst, J. J. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.10.6855 · Cited by 401 · cited 1×
“In addition, arterial blood was analyzed for GIP (12) From the (1)Department of Clinical Physiology/Nuclear Medicine, Bispebjerg Hospital, Copenhagen, Denmark; the (2)Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark; and the (3)Department of Endocrinology, Hvidovre Hospital, Hvidovre, D…”
MethodSelf-citationDeacon, C. F. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.10.3575 · Cited by 301
Functional GIP Receptors Are Present on Adipocytes
Yip, R. G.-C., Boylan, M. O., Kieffer, T. J., & Wolfe, M. M. (1998) · Endocrinology · doi:10.1210/endo.139.9.6288 · Cited by 237 · cited 1×
“In vitro studies have shown that GIP stimulates lipolysis (16,17).”
BackgroundRuge, T., Hodson, L., Cheeseman, J., Dennis, A. L., Fielding, B. A., Humphreys, S. M., Frayn, K. N., & Karpe, F. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2090 · Cited by 156 · cited 2×
“This suggests that FFA derived from LPL-mediated hydrolysis of the circulating TAG was directed into the adipose tissue probably to be esterified and stored, similar to what has been shown previously in subjects examined in the fed state (8).”
BackgroundResultEffect of gastric inhibitory polypeptide on plasma levels of chylomicron triglycerides in dogs.
Wasada, T., McCorkle, K., Harris, V, Kawai, K., Howard, B., & Unger, R. H. (1981) · Journal of Clinical Investigation · doi:10.1172/jci110335 · Cited by 153 · cited 1×
“Several animal studies support the idea that glucose-dependent insulinotropic polypeptide (GIP) may play a direct role in lipid metabolism, which could be to ensure efficient deposition of dietary fat in body stores in times of plenty (1,2).”
BackgroundSamra, J. S., Simpson, E. J., Clark, M. L., Forster, C. D., Humphreys, S. M., Macdonald, I. A., & Frayn, K. N. (1996) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1996.271.5.e834 · Cited by 102 · cited 1×
“(15) have demonstrated that when adipose tissue blood flow increased by infusion of adrenaline, TAG hydrolysis increased exactly in parallel with increased blood flow, implying that TAG hydrolysis is normally limited by substrate delivery, which is consistent with our present study.”
ResultBeck, B., & Max, J. (1983) · Regulatory Peptides · doi:10.1016/0167-0115(83)90276-8 · Cited by 91
On the role of glucose-dependent insulintropic polypeptide in postprandial metabolism in humans
Asmar, M., Tangaa, W., Madsbad, S., Hare, K., Astrup, A., Flint, A., Bülow, J., & Holst, J. J. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00639.2009 · Cited by 83 · cited 1×
“We recently studied the effect of GIP on the removal rates of plasma triacylglycerol (TAG) and on free fatty acid (FFA) concentrations, which were increased after either a mixed meal or infusion of Intralipid and insulin (6).”
BackgroundSelf-citation
Research works printed but not linked: 1
- Ekberg, 2001, Stimulation of blood flow by C-peptide in patients with type 1 diabetes, Diabetologia, 44, A323
Cited by
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Self-citationPharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500
“…consistent impact on adipocyte lipid metabolism, free fatty acids, or triglycerides in human subjects, the combination of GIP plus insulin had a greater effect to increase adipose tissue blood flow in lean nondiabetic human subjects than did infusion of insulin or GIP alone (Asmar et al., 2010).”
BackgroundTirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis
Loomba, R., Hartman, M. L., Lawitz, E. J., Vuppalanchi, R., Boursier, J., Bugianesi, E., Yoneda, M., Behling, C., Cummings, O. W., Tang, Y., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2401943 · Cited by 1,005
Coskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882
Frias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815
Impact of postprandial glycaemia on health and prevention of disease
Blaak, E. E., Antoine, J. ‐., Benton, D., Björck, I., Bozzetto, L., Brouns, F., Diamant, M., Dye, L., Hulshof, T., Holst, J. J., et al. (2012) · Obesity Reviews · doi:10.1111/j.1467-789x.2012.01011.x · Cited by 477
Self-citationHow May GIP Enhance the Therapeutic Efficacy of GLP-1?
Samms, R. J., Coghlan, M. P., & Sloop, K. W. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2020.02.006 · Cited by 419
Nauck, M. A., Quast, D. R., Wefers, J., & Pfeiffer, A. F. H. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14496 · Cited by 388
Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease.
Baggio, L. L., & Drucker, D. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101090 · Cited by 299
Kopp, K. O., Glotfelty, E. J., Li, Y., & Greig, N. H. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106550 · Cited by 298
Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
Liu, Q. K. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1431292 · Cited by 265
Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism
Mroz, P. A., Finan, B., Gelfanov, V., Yang, B., Tschöp, M. H., DiMarchi, R. D., & Perez-Tilve, D. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2018.12.001 · Cited by 229
Gasbjerg, L. S., Helsted, M. M., Hartmann, B., Jensen, M. H., Gabe, M. B. N., Sparre-Ulrich, A. H., Veedfald, S., Stensen, S., Lanng, A. R., Bergmann, N. C., et al. (2019) · Diabetes · doi:10.2337/db18-1123 · Cited by 193
“In this study, we assessed the individual and combined contributions of endogenous GIP and GLP-1 to the postprandial changes in glucose and glucoregulatory hormones using the novel GIP receptor antagonist GIP(3-30)NH2 and the well-established GLP-1 receptor antagonist exendin(9-39)NH2.”
BackgroundMethodInfluentialSelf-citationAdipose Tissue and Metabolic Health
An, S.-M., Cho, S.-H., & Yoon, J. C. (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0011 · Cited by 184
“GIP has been reported to enhance lipid clearance by enhancing triglyceride storage in WAT, increase WAT blood flow, stimulate glucose uptake, and lower free fatty acids in humans [93,94].”
BackgroundPowell, D. R., Smith, M., Greer, J., Harris, A., Zhao, S., DaCosta, C., Mseeh, F., Shadoan, M. K., Sands, A., Zambrowicz, B., et al. (2013) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.203364 · Cited by 184
“…challenge (Gorboulev et al., 2012), which suggests that LX4211 might lower postprandial GIP levels; this is important because decreased postprandial GIP levels may benefit patients with T2DM (Flint et al., 1998; Baggio and Drucker, 2007; Chia et al., 2009; Asmar et al., 2010; Reimann, 2010).”
BackgroundSecretion of Glucose-Dependent Insulinotropic Polypeptide in Patients With Type 2 Diabetes
Calanna, S., Christensen, M., Holst, J. J., Laferrère, B., Gluud, L. L., Vilsbøll, T., & Knop, F. K. (2013) · Diabetes Care · doi:10.2337/dc13-0465 · Cited by 158
“Besides the renowned insulinotropic effect of GIP, the hormone also exerts glucagonotropic and adipogenic effects (7,8).”
BackgroundSelf-citationTargeting the Incretin/Glucagon System With Triagonists to Treat Diabetes
Capozzi, M. E., DiMarchi, R. D., Tschöp, M. H., Finan, B., & Campbell, J. E. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00117 · Cited by 153
Regulation of human subcutaneous adipose tissue blood flow
Frayn, K. N., & Karpe, F. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.200 · Cited by 173
Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes
Tan, Q., Akindehin, S. E., Orsso, C. E., Waldner, R. C., DiMarchi, R. D., Müller, T. D., & Haqq, A. M. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.838410 · Cited by 146
The intestine as an endocrine organ and the role of gut hormones in metabolic regulation
Bany Bakar, R., Reimann, F., & Gribble, F. M. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00830-y · Cited by 144
“Several studies have demonstrated that GIP receptor activation in adipose tissue acts in concert with insulin to increase lipid accumulation 149,150 , glucose uptake 144,151 , de novo lipogenesis 145 and FFA re-esterification 146 .”
BackgroundTargeting the glucagon receptor family for diabetes and obesity therapy
Cho, Y. M., Merchant, C. E., & Kieffer, T. J. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.05.009 · Cited by 156
Regmi, A., Aihara, E., Christe, M. E., Varga, G., Beyer, T. P., Ruan, X., Beebe, E., O’Farrell, L. S., Bellinger, M. A., Austin, A. K., et al. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.05.010 · Cited by 130
Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms
Campbell, J. E. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101139 · Cited by 133
Asmar, M., Asmar, A., Simonsen, L., Gasbjerg, L. S., Sparre-Ulrich, A. H., Rosenkilde, M. M., Hartmann, B., Dela, F., Holst, J. J., & Bülow, J. (2017) · Diabetes · doi:10.2337/db17-0480 · Cited by 132
“We have previously demonstrated that GIP infusions in the presence of elevated insulin concentrations increased ATBF and stimulated triacylglyceride (TAG) deposition in adipose tissue in lean humans (1), suggesting that GIP together with insulin are controllers of postprandial fat deposition.”
BackgroundMethodResultInfluentialSelf-citationNutrient detection by incretin hormone secreting cells
Diakogiannaki, E., Gribble, F. M., & Reimann, F. (2012) · Physiology & Behavior · doi:10.1016/j.physbeh.2011.12.001 · Cited by 123
Incretin Hormones and Type 2 Diabetes—Mechanistic Insights and Therapeutic Approaches
Boer, G. A., & Holst, J. J. (2020) · Biology · doi:10.3390/biology9120473 · Cited by 153
Self-citationPirro, V., Roth, K. D., Lin, Y., Willency, J. A., Milligan, P. L., Wilson, J. M., Ruotolo, G., Haupt, A., Newgard, C. B., & Duffin, K. L. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab722 · Cited by 113
Is adipose tissue metabolically different at different sites?
Gil, A., Olza, J., Gil-Campos, M., Gomez-Llorente, C., & Aguilera, C. M. (2011) · International Journal of Pediatric Obesity · doi:10.3109/17477166.2011.604326 · Cited by 115
Sparre‐Ulrich, A. H., Hansen, L. S., Svendsen, B., Christensen, M., Knop, F. K., Hartmann, B., Holst, J. J., & Rosenkilde, M. M. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13323 · Cited by 114
“In an attempt to develop GIP receptor antagonists to be used in humans, for instance, as a putative therapeutic against obesity (Asmar et al., 2010; Ahlqvist et al., 2013), we set out to investigate functional differences between rodents and human within the GIP system in terms of ligand binding…”
BackgroundInfluentialSelf-citationMechanisms responsible for excess weight loss after bariatric surgery
Ionut, V., & Bergman, R. N. (2011) · Journal of Diabetes Science and Technology · doi:10.1177/193229681100500536 · Cited by 105
Mohammad, S., Patel, R. T., Bruno, J., Panhwar, M. S., Wen, J., & McGraw, T. E. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.00256-14 · Cited by 104
Zarrinpar, A., & Loomba, R. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12084 · Cited by 103
Glucose-dependent insulinotropic polypeptide (GIP)
Müller, T. D., Adriaenssens, A. E., Ahrén, B., Blüher, M., Birkenfeld, A. L., Campbell, J. E., Coghlan, M. P., D’Alessio, D. D., Deacon, C. F., DelPrato, S., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102118 · Cited by 112
Self-citationGasbjerg, L. S., Christensen, M., Hartmann, B., Lanng, A. R., Sparre‐Ulrich, A. H., Gabe, M. B. N., Dela, F., Vilsbøll, T., Holst, J. J., ROSENKILDE, M. M., et al. (2017) · Diabetologia · doi:10.1007/s00125-017-4447-4 · Cited by 103
“However, GIP(1-42) has other physiological effects, and has been shown to inhibit bone resorption [10], increase adipose tissue blood flow and stimulate fat deposition [11, 12].”
BackgroundSelf-citationGabe, M. B. N., Sparre‐Ulrich, A. H., Pedersen, M. F., Gasbjerg, L. S., Inoue, A., Bräuner‐Osborne, H., Hartmann, B., & ROSENKILDE, M. M. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.01.040 · Cited by 96
Glucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents
Gasbjerg, L. S., Gabe, M. B. N., Hartmann, B., Christensen, M. B., Knop, F. K., Holst, J. J., & Rosenkilde, M. M. (2018) · Peptides · doi:10.1016/j.peptides.2017.11.021 · Cited by 85
“Furthermore, GIP increases the triacylglycerol (TAG) uptake in adipose tissue [8] and decreases bone resorption [9].”
BackgroundSelf-citationHodge, D., Marsh, W. J., Parker, H. E., Ogunnowo-Bada, E., Riches, C. H., Habib, A. M., Evans, M. L., Gribble, F. M., & Reimann, F. (2012) · Diabetologia · doi:10.1007/s00125-012-2663-5 · Cited by 87
Christensen, M., Calanna, S., Sparre-Ulrich, A. H., Kristensen, P. L., Rosenkilde, M. M., Faber, J., Purrello, F., van Hall, G., Holst, J. J., Vilsbøll, T., et al. (2015) · Diabetes · doi:10.2337/db14-0440 · Cited by 82
“This was unexpected, as a preponderance of evidence including human in vivo data supports a role for GIP combined with insulin in stimulating postprandial lipogenesis (20,21).”
BackgroundSelf-citationKoliaki, C. C., Liatis, S., Dalamaga, Μ., & Kokkinos, A. D. (2020) · Current Obesity Reports · doi:10.1007/s13679-020-00396-9 · Cited by 92
The effects of dual GLP-1/GIP receptor agonism on glucagon secretion-A Review
Mathiesen, D. S., Bagger, J. I., Bergmann, N. C., Lund, A., Christensen, M. B., Vilsbøll, T., & Knop, F. K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174092 · Cited by 80
“This indicates pleiotropic functions, and GIP has been suggested to mediate a reduction in bone resorption [96], increase triacylglyceride deposition in adipose tissue [97] and increase blood flow to the adipose tissue and intestines [97,98].”
BackgroundThondam, S. K., Cuthbertson, D. J., & Wilding, J. P. H. (2020) · Peptides · doi:10.1016/j.peptides.2019.170208 · Cited by 77
High glycemic index metabolic damage – a pivotal role of GIP and GLP-1
Pfeiffer, A. F. H., & Keyhani-Nejad, F. (2018) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2018.03.003 · Cited by 74
“GIP appears to increase fat storage in adipocytes [39,40] and participates in adipose tissue immune regulation [41–43].”
Thondam, S. K., Daousi, C., Wilding, J. P. H., Holst, J. J., Ameen, G. I., Yang, C., Whitmore, C., Mora, S., & Cuthbertson, D. J. (2017) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00347.2016 · Cited by 71
“Acute GIP infusion in lean healthy males (with hyperinsulinemia and hyperglycemia) increases adipose tissue blood flow, triacylglycerol (TAG) hydrolysis, and nonesterified fatty acid (NEFA) reesterification, thus promoting triglyceride deposition (5, 6).”
Self-citationHolst, J. J., Albrechtsen, N. J. W., Rosenkilde, M. M., & Deacon, C. F. (2019) · Comprehensive Physiology · doi:10.1002/cphy.c180013 · Cited by 54
Self-citationGIPR Is Predominantly Localized to Nonadipocyte Cell Types Within White Adipose Tissue
Campbell, J. E., Beaudry, J. L., Svendsen, B., Baggio, L. L., Gordon, A. N., Ussher, J. R., Wong, C. K., Gribble, F. M., D’Alessio, D. A., Reimann, F., et al. (2022) · Diabetes · doi:10.2337/db21-1166 · Cited by 68
The Role of Gastrointestinal Hormones in Hepatic Lipid Metabolism
Mells, J., & Anania, F. (2013) · Seminars in Liver Disease · doi:10.1055/s-0033-1358527 · Cited by 70
“85,86 87 Finally, a recent clinical study indicates that GIP in nondiabetic NASH patients may exacerbate fatty acid accumulation and biosynthesis, and that GIP antagonism would be clinically beneficial.”
BackgroundGlucose-dependent insulinotropic polypeptide (GIP) and cardiovascular disease
Heimbürger, S. M., Bergmann, N. C., Augustin, R., Gasbjerg, L. S., Christensen, M. B., & Knop, F. K. (2020) · Peptides · doi:10.1016/j.peptides.2019.170174 · Cited by 67
Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH
Svegliati-Baroni, G., Patrício, B., Lioci, G., Macedo, M. P., & Gastaldelli, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165820 · Cited by 66
Møller, C. L., Vistisen, D., Færch, K., Johansen, N. B., Witte, D. R., Jonsson, A., Pedersen, O., Hansen, T., Lauritzen, T., Jørgensen, M. E., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3133 · Cited by 62
Self-citationVascular Biology of Glucagon Receptor Superfamily Peptides: Mechanistic and Clinical Relevance
Pujadas, G., & Drucker, D. J. (2016) · Endocrine Reviews · doi:10.1210/er.2016-1078 · Cited by 65
Asmar, M., Simonsen, L., Asmar, A., Holst, J. J., Dela, F., & Bülow, J. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1933 · Cited by 61
Self-citationReichkendler, M. H., Auerbach, P., Rosenkilde, M., Christensen, A. N., Holm, S., Petersen, M. B., Lagerberg, A., Larsson, H. B. W., Rostrup, E., Mosbech, T. H., et al. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00128.2013 · Cited by 59
Self-citationWu, T., Rayner, C. K., & Horowitz, M. (2015) · Handbook of experimental pharmacology · doi:10.1007/164_2015_9 · Cited by 68
Glucose‐dependent insulinotropic polypeptide signaling in pancreatic β‐cells and adipocytes
McIntosh, C. H., Widenmaier, S., & Kim, S. (2012) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2012.00196.x · Cited by 57
Asmar, M., Simonsen, L., Arngrim, N., Holst, J. J., Dela, F., & Bülow, J. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.73 · Cited by 57
Self-citationDiabetes and obesity treatment based on dual incretin receptor activation: ‘twincretins’
Skow, M. A., Bergmann, N. C., & Knop, F. K. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12685 · Cited by 56
“Although a fat-depositing effect of GIP in humans has been suggested [23], the effects of GIP on lipid metabolism and body weight in humans remain to be established.”
BackgroundZhou, Q., Lei, X., Fu, S., Liu, P., Long, C., Wang, Y., Li, Z., Xie, Q., & Chen, Q. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01198-4 · Cited by 55
“Studies have shown that the GIP/ GLP-1Ras action did not affect the incretin effects on GIP-stimulated insulin secretion, and strengthened the inherent efficacy and broadened their therapeutic range when both the GIP receptor and GLP-1 receptor are activated [32, 33].”
BackgroundDarwiche, G., Höglund, P., Roth, B., Larsson, E., Sjöberg, T., Wohlfart, B., Steen, S., & Ohlsson, B. (2016) · Food & Nutrition Research · doi:10.3402/fnr.v60.32594 · Cited by 55
“and hyperglycemia is strongly involved in lipid regulation in humans (46).”
BackgroundGögebakan, Ö., Andres, J., Biedasek, K., Mai, K., Kühnen, P., Krude, H., Isken, F., Rudovich, N., Osterhoff, M. A., Kintscher, U., et al. (2012) · Diabetes · doi:10.2337/db10-0902 · Cited by 50
“FFAs slightly increased during saline administration.”
BackgroundResultInfluentialAltered glucose metabolism after bariatric surgery: What's GLP-1 got to do with it?
Smith, E. P., Polanco, G., Yaqub, A., & Salehi, M. (2017) · Metabolism · doi:10.1016/j.metabol.2017.10.014 · Cited by 54
Ugleholdt, R., Pedersen, J., Bassi, M. R., Füchtbauer, E.-M., Jørgensen, S. M., Kissow, H.-L., Nytofte, N., Poulsen, S. S., Rosenkilde, M. M., Seino, Y., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.311779 · Cited by 49
Self-citationNutrition and l and K-enteroendocrine cells
Gutierrez-Aguilar, R., & Woods, S. C. (2011) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e32834190b5 · Cited by 47
Zafer, M., Tavaglione, F., Romero‐Gómez, M., & Loomba, R. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70196 · Cited by 47
“In human studies, GIP promotes lipid disposal by enhancing tri-glycerides clearance through increased WAT blood flow, increased adipocyte insulin sensitivity, and recruitment of insulin-sensitive LPL, and resultant triglycerides synthesis and storage in WAT [45, 61].”
Effects of endogenous GIP in patients with type 2 diabetes
Stensen, S., Gasbjerg, L. S., Krogh, L. L., Skov-Jeppesen, K., Sparre-Ulrich, A. H., Jensen, M. H., Dela, F., Hartmann, B., Vilsbøll, T., Holst, J. J., et al. (2021) · European Journal of Endocrinology · doi:10.1530/eje-21-0135 · Cited by 44
Self-citationDirect cardiovascular effects of glucagon like peptide-1
Sheikh, A. (2013) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-5-47 · Cited by 45
Glucagon‐like peptide‐1 elicits vasodilation in adipose tissue and skeletal muscle in healthy men
Asmar, A., Asmar, M., Simonsen, L., Madsbad, S., Holst, J. J., Hartmann, B., Sorensen, C. M., & Bülow, J. (2017) · Physiological Reports · doi:10.14814/phy2.13073 · Cited by 41
“It is well described (Bulow et al. 1987a; Karpe et al. 2002a), that ATBF increases postprandially and that hyperinsulinemia per se cannot account for this increase (Asmar et al. 2010).”
BackgroundSelf-citationAsmar, M., Arngrim, N., Simonsen, L., Asmar, A., Nordby, P., Holst, J. J., & Bülow, J. (2016) · Nutrition & Diabetes · doi:10.1038/nutd.2016.15 · Cited by 42
Self-citationBoer, G. A., Keenan, S. N., Miotto, P. M., Holst, J. J., & Watt, M. J. (2021) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00646.2020 · Cited by 38
Self-citationHartstra, A. V., Nieuwdorp, M., & Herrema, H. (2016) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2016.08.009 · Cited by 41
GIP-induced vasodilation in human adipose tissue involves capillary recruitment
Asmar, M., Asmar, A., Simonsen, L., Dela, F., Holst, J. J., & Bülow, J. (2019) · Endocrine Connections · doi:10.1530/ec-19-0144 · Cited by 37
Self-citationAlyami, J., Whitehouse, E., Yakubov, G. E., Pritchard, S. E., Hoad, C. L., Blackshaw, E., Heissam, K., Cordon, S. M., Bligh, H. F. J., Spiller, R. E., et al. (2019) · British Journal Of Nutrition · doi:10.1017/s0007114519001880 · Cited by 41
“524 GIP in combination with hyperinsulinaemia and hyperglycaemia has been shown to promote 525 triacylglycerol absorption in adipose tissue ((71)), with high plasma levels of GIP associated 526 with unhealthy body fat distribution ((72)).”
BackgroundSearching for the physiological role of glucose‐dependent insulinotropic polypeptide
Holst, J. J., Windeløv, J. A., Boer, G. A., Pedersen, J., Svendsen, B., Christensen, M., Torekov, S., Asmar, M., Hartmann, B., & Nissen, A. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12488 · Cited by 36
Self-citationGIP’s involvement in the pathophysiology of type 2 diabetes
Christensen, M. B., Gasbjerg, L. S., Heimbürger, S. M., Stensen, S., Vilsbøll, T., & Knop, F. K. (2020) · Peptides · doi:10.1016/j.peptides.2019.170178 · Cited by 35
Gut hormones and appetite regulation
Hong, S.-H., & Choi, K. M. (2024) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000859 · Cited by 35
Paschetta, E., Hvalryg, M., & Musso, G. (2011) · Obesity Reviews · doi:10.1111/j.1467-789x.2011.00897.x · Cited by 32
Recent advances of GIP and future horizons
Holst, J. J., & Rosenkilde, M. M. (2020) · Peptides · doi:10.1016/j.peptides.2019.170230 · Cited by 33
Self-citationDirect effect of incretin hormones on glucose and glycerol metabolism and hemodynamics
Karstoft, K., Mortensen, S. P., Knudsen, S. H., & Solomon, T. P. J. (2015) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00520.2014 · Cited by 32
“Whereas this lack of in vivo effect on lipolysis has previously been shown for GLP-1 (33), GIP has previously been shown to increase fatty acid reesterification in subcutaneous abdominal adipose tissue (4) and to stimulate lipolysis in perfused rat Fig.”
BackgroundOhlsson, B. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7303 · Cited by 39
“Both luminal carbohydrates and fat induce postprandial secretion of the incretins glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) (12,13), which also play roles in the regulation of gastrointestinal motility, obesity development, and secretion of luminal digestive enzymes (13-16).”
Baldassano, S., Gasbjerg, L. S., Kizilkaya, H. S., ROSENKILDE, M. M., Holst, J. J., & Hartmann, B. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00492 · Cited by 34
Self-citationDe Block, C. E. M., Dirinck, E., Verhaegen, A., & Van Gaal, L. F. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14640 · Cited by 29
Heimbürger, S. M. N., Hoe, B., Nielsen, C. N., Bergmann, N. C., Skov‐Jeppesen, K., Hartmann, B., Holst, J. J., Dela, F., Overgaard, A. J., Størling, J., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac542 · Cited by 34
Self-citationMetabolism of GIP and the contribution of GIP to the glucose-lowering properties of DPP-4 inhibitors
Deacon, C. F. (2020) · Peptides · doi:10.1016/j.peptides.2019.170196 · Cited by 31
Pelle, M. C., Provenzano, M., Zaffina, I., Pujia, R., Giofrè, F., Lucà, S., Andreucci, M., Sciacqua, A., & Arturi, F. (2021) · Life · doi:10.3390/life12010029 · Cited by 28
“Moreover, human studies evidenced that the GIP receptors was down regulated in adipose tissue in insulin-resistant states, but acute infusion of GIP under hyperinsulinism and hyperglycemia conditions promoted adipose tissue glucose uptake and triglyceride hydrolysis [74,104,120,121].”
BackgroundGuccio, N., Gribble, F. M., & Reimann, F. (2022) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-062320-113625 · Cited by 35
Filippou, A., Berry, S. E., Baumgartner, S., Mensink, R. P., & Sanders, T. A. B. (2014) · European Journal of Clinical Nutrition · doi:10.1038/ejcn.2014.49 · Cited by 28
The interplay of glucose-dependent insulinotropic polypeptide in adipose tissue
Kagdi, S., Lyons, S. A., & Beaudry, J. L. (2024) · Journal of Endocrinology · doi:10.1530/joe-23-0361 · Cited by 33
From endocrine to rheumatism: do gut hormones play roles in rheumatoid arthritis?
Chen, C., & Tsai, C. (2013) · Rheumatology · doi:10.1093/rheumatology/ket255 · Cited by 29
Incretin Hormones: The Link between Glycemic Index and Cardiometabolic Diseases
Salvatore, T., Nevola, R., Pafundi, P. C., Monaco, L., Ricozzi, C., Imbriani, S., Rinaldi, L., & Sasso, F. C. (2019) · Nutrients · doi:10.3390/nu11081878 · Cited by 33
“Animal and human studies report a physiological role for GIP in the nutrient uptake into adipose tissues and, therefore, in the pathogenesis of obesity [85,86].”
BackgroundGribble, F. M., Reimann, F., & Roberts, G. P. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809954-4.00002-5 · Cited by 30
Kokkinos, A. D., Tsilingiris, D., le Roux, C. W., Rubino, F., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2019.153960 · Cited by 29
Tobin, L., Simonsen, L., & Bülow, J. (2011) · Clinical Physiology and Functional Imaging · doi:10.1111/j.1475-097x.2011.01041.x · Cited by 30
“In the study with GIP infusion, blood flow increased significantly in the abdominal subcutaneous adipose tissue compared to the saline infusion control study (Asmar et al., 2010).”
BackgroundSelf-citationSachs, S., Götz, A., Finan, B., Feuchtinger, A., DiMarchi, R. D., Döring, Y., Weber, C., Tschöp, M. H., Müller, T. D., & Hofmann, S. M. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01940-2 · Cited by 24
“GIP plays a physiologic role in the disposition of ingested fat by stimulating lipid uptake in subcutaneous adipose tissue [17–21].”
BackgroundBulum, T. (2022) · Biomedicines · doi:10.3390/biomedicines10102586 · Cited by 31
“In the insulin resistance state characterized by high serum levels of glucose and insulin, GIP increases circulation in adipose tissue, resulting in higher triglyceride clearance [52].”
BackgroundRabbani, N., & Thornalley, P. J. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111905 · Cited by 25
Incretin-Based Therapy and Type 2 Diabetes
Hare, K. J., & Knop, F. K. (2010) · Vitamins and hormones · doi:10.1016/b978-0-12-381517-0.00015-1 · Cited by 24
Gut–adipose tissue crosstalk: A bridge to novel therapeutic targets in metabolic syndrome?
Silva, D., & Matafome, P. N. (2020) · Obesity Reviews · doi:10.1111/obr.13130 · Cited by 23
A Contemporary Rationale for Agonism of the GIP Receptor in the Treatment of Obesity
Samms, R. J., & Sloop, K. W. (2025) · Diabetes · doi:10.2337/dbi24-0026 · Cited by 27
“In addition to its insulinotropic effects, GIP is a nutrient-induced factor that coordinates the storage of dietary fat in adipose tissue (83 – 85), with infusion studies in humans showing that GIP reduces plasma triglycerides by promoting their disposal in WAT (69,86 – 88).”
West, J. A., Ghosh, S. S., Parkes, D. G., Tsakmaki, A., Grønlund, R. V., Pedersen, P. J., MAGGS, D. G., Rajagopalan, H., & Bewick, G. A. (2021) · PLoS ONE · doi:10.1371/journal.pone.0249239 · Cited by 19
“GIP increases the activity of lipoprotein lipase [26], elevating triglyceride accumulation in fat tissue [27] and inhibiting lipolysis [28].”
BackgroundSalehi, M., DeFronzo, R. A., & Gastaldelli, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147667 · Cited by 21
De Fano, M., Malara, M., Vermigli, C., & Murdolo, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168650 · Cited by 17
“Additional research verified that GIP did not alter energy metabolism or appetite, nor did it alter TAG clearance in the absence of insulin when compared with saline infusion of lipid emulsions [114].”
Background
Metadata
- Authors
- Asmar, M., Simonsen, L., Madsbad, S., Stallknecht, B., Holst, J. J., & Bülow, J.
- Affiliations
- University of Copenhagen (DK)
- Bispebjerg Hospital (DK)
- Hvidovre Hospital (DK)
- Corresponding author
- Bülow, Jens
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2010-06-14
- Volume
- 59
- Issue
- 9
- Pages
- 2160-2163
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC2927937
- OpenAlex
- W2122333141
- Cited by
- 184
- References
- 19
- Citations by year
- 2026: 25 · 2025: 17 · 2024: 14 · 2023: 14 · 2022: 15 · 2021: 9 · 2020: 8 · 2019: 18 · 2018: 9 · 2017: 6 · 2016: 9 · 2015: 5 · 2014: 6 · 2013: 9 · 2012: 8
- FWCI
- 6.54
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
- Keywords
- glucose-dependent insulinotropic polypeptide, fatty acid re-esterification, subcutaneous abdominal fat, adipose tissue blood flow, lipolysis, free fatty acid release, glucose uptake, lipid metabolism
- MeSH terms
- Adult, Blood Glucose, C-Peptide, Fatty Acids, Gastric Inhibitory Polypeptide, Glycerol, Humans, Hyperglycemia, Hyperinsulinism, Male, Thinness, Triglycerides, Glucose Clamp Technique, Subcutaneous Fat, Abdominal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.